Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Bioengineered Protein Drugs Market Heading Into 2029?

There has been prominent growth in the size of the bioengineered protein drugs market in the recent past. The market, which is estimated to be worth $406.39 billion in 2024, is expected to rise to $435.17 billion in 2025, with a compound annual growth rate (CAGR) of 7.1%. Factors influencing this surge during the historical phase include improved knowledge of diseases, approval by regulatory bodies, a higher occurrence of chronic illnesses, plus collaborations and partnerships leading to market expansion.

The market size of bioengineered protein drugs is anticipated to witness substantial expansion in the succeeding few years, ballooning to “$593.3 billion in 2029 with a CAGR of 8.1%.” This projected growth during the forecast period can be ascribed to elements such as evolving trends in personalized medicine, broadening therapeutic applications, burgeoning markets, concentrated efforts on rare diseases, and the enhancement of healthcare infrastructure. Noteworthy trends for the forecast period encompass progress in protein engineering, intensified concentration on monoclonal antibodies, personalized medicine and targeted therapies, the arrival of next-generation biologics, and the optimization of the manufacturing process.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10180&type=smp

Which Factors Are Pushing The Bioengineered Protein Drugs Market Forward?

The augmentation in the prevalence of chronic diseases is anticipated to drive the expansion of the bioengineered protein drug market. Chronic diseases are those that individuals grapple with for longer than a year, necessitating continuous medical attention and limiting daily physical activities. Bioengineered protein drugs employ tailored protein therapies for the treatment of these long-term diseases, prominently in oncology and regenerative medicine through the use of combinatorial and logical methods. For example, as per the September 2022 Highlights from the World Health Organization (WHO), a Switzerland-based global health entity, there were 41 million fatalities, with noncommunicable diseases (NCDs) or chronic diseases causing 74% of these deaths globally. The yearly global death toll included 17.9 million due to cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Consequently, the rise in chronic diseases is fuelling the demand for bioengineered protein drugs.

Which Segment Held The Largest Share In The Bioengineered Protein Drugs Market In 2025?

The bioengineered protein drugs market covered in this report is segmented –

1) By Drug Type: Recombinant Protein, Vaccine, Peptide Antibiotics, Therapeutic Enzymes, Other Drug Type

2) By Technology: Bioreactors, Fractionation, Genetically Modified Organisms, Genetic Engineering, Pharming, Cell Culture, Microbial Cell Fermentation, Other Technology

3) By Application: Autoimmune, Heart, Congenital, Infectious Diseases, Cancer, Diabetes, Arthritis, Other Application

4) By End User: Pharmaceutical, Contract Research Organizations, Research Institutes, Biotechnology Companies

Subsegments:

1) By Recombinant Protein: Monoclonal Antibodies, Hormones, Cytokines

2) By Vaccine: Recombinant Vaccines, DNA Vaccines

3) By Peptide Antibiotics: Lipopeptide Antibiotics, Glycopeptide Antibiotics

4) By Therapeutic Enzymes: Enzyme Replacement Therapies, Biosimilar Enzymes

5) By Other Drug Type: Fusion Proteins, Antibody-Drug Conjugates (ADCs)

Which Trends Are Redefining The Future Landscape Of The Bioengineered Protein Drugs Industry?

Major firms in the bioengineered protein drug market are pursuing a strategy of establishing strategic partnerships to supply critical bioengineered protein drugs to businesses and governments. Strategic partnerships involve companies utilizing each other’s strengths and resources to attain mutual success and benefits. For example, Future Fields, a Canadian biotechnology company, formed a partnership with Jenthera Therapeutics, another Canada-based biotechnology company specializing in creating inventive therapies for rare and complex diseases, in June 2023. Their objective with this alliance is to engineer a new cancer combating protein using Future Fields’ EntoEngine platform for affordable and sustainable large-scale production.

Which Organizations Are Driving Progress In The Bioengineered Protein Drugs Industry?

Major companies operating in the bioengineered protein drugs market include Abbvie Inc., Amgen Inc., Astrazeneca PLC, Bayer HealthCare Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Novo Nordisk A/S, Sanofi S.A., Grifols S.A., Adma Biologics Inc., CSL Limited, Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, Merck & Co. Inc., Pfizer Inc., Biogen Inc., Bristol-Myers Squibb Company, Genentech Inc., Lonza Group AG, MedImmune LLC, Regeneron Pharmaceuticals Inc., Shire plc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shanghai United Cell Biotechnology Co. Ltd., Panacea Biotec Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/bioengineered-protein-drugs-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Bioengineered Protein Drugs Industry?

North America was the largest region in the bioengineered protein drugs market in 2024. The regions covered in the bioengineered protein drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10180&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model